港股異動 | 諾誠健華-B(9969.HK)一度大漲10%破頂 市值達460億港元
格隆匯7月12日丨諾誠健華-B(9969.HK)尾盤一度急漲至10%,報30.9港元再度刷新歷史新高價,暫成交1.26億港元,總市值達460億港元。諾誠健華8日宣佈,公司布魯頓酪氨酸激酶(BTK)抑制劑奧布替尼用於治療多發性硬化(MS)的臨牀試驗申請(CTA)已經獲取波蘭主管當局和烏克蘭衞生部以及倫理委員會的批准,即將在這兩個國家開展臨牀II期研究。此前,奧布替尼已獲美國與中國開展臨牀II期研究。根據弗若斯特沙利文公司的分析數據,全球MS市場規模2018年達到230億美元,並預計到2030年達到489億美元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.